GlassScriptPhysician profile
Madhuri Vusirikala
NPI 1700899283
$21,525.97
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $74.99 · 2021: $1,982 · 2022: $9,071.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $5,018.64 | 2019 | |
| Sanofi-Aventis U.S. LLC | $4,668.51 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $3,990.00 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $2,808.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $2,372.00 | 2022 | |
| Celgene Corporation | $1,323.69 | 2019 | |
| Amgen INC. | $1,126.81 | 2019 | |
| Astellas Pharma US INC | $194.95 | 2019 | |
| Adaptive Biotechnologies Corporation | $22.61 | 2022 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhuri Vusirikala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.